1 May 2020 in OncoTargets and Therapy
Purpose: Conventional chemotherapy and enucleation usually fail to cure advanced retinoblastoma. We investigated the retinoblastoma immune microenvironment and the efficacy of the combination of dinutuximab and CD16-expressing NK-92MI (NK-92MIhCD16-GFP) cells on retinoblastoma cells in this study. Patients and Methods: Immunohistochemistry and flow cytometry (FC) were performed to assess the expression level of GD2 in retinoblastoma tissues and cells. Gene set enrichment analysis (GSEA), immunohistochemisrztry and immunocytochemistry were conducted to assess the retinoblastoma immune microenvironment and the integrity of the blood-retinal barrier (BRB). After overexpressing CD16 in NK-92MI cells, fluorescence-activated cell sorting (FACS) was applied to select the positive subpopulation. LDH assays and FC were used to detect LDH release and apoptosis in retinoblastoma cells subjected to a combination of dinutuximab and NK-92MIhCD16-GFP cells. Finally, the release of perforin-granzyme B and the expression of CD107a in NK-92MIhCD16-GFP stimulated by retinoblastoma cells were assessed via enzyme-linked immunosorbent assays (ELISAs) and FC in the presence of dinutuximab or an isotype control. Results: GD2 was heterogeneously expressed in retinoblastoma tissues and cell lines and positively correlated with proliferation and staging. GSEA revealed the immunosuppressive status of retinoblastoma microenvironment. The immune cell profile of retinoblastoma tissues and vitreous bodies suggested BRB destruction. LDH release and apoptosis in retinoblastoma cells caused by NK-92MIhCD16-GFP cells were significantly enhanced by dinutuximab. Finally, the release of perforin-granzyme B and the expression of CD107a in NK-92MIhCD16-GFP cells stimulated by retinoblastoma cells were obviously increased by dinutuximab. Conclusion: This study indicates that retinoblastoma impairs the integrity of the BRB and contributes to dysregulated immune cell infiltrates. GD2 is a specific target for natural killer (NK) cell-based immunotherapy and that the combination of dinutuximab and NK-92MIhCD16-GFP cells exerts potent antitumor effects through antibody-dependent cell-mediated cytotoxicity.
20 December 2024 in Cancer Cytopathology
19 March 2025 in Cancer Cytopathology
19 June 2026 in The Journal of Molecular Diagnostics
NTRK gene fusions are rare but actionable oncogenic drivers, and their timely detection is critical for guiding TRK-targeted therapy. Conventional methods such as immunohistochemistry, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, and next-generation sequencing can be limited by variable sensitivity, cost, and slow turnaround times. We evaluated the Idylla GeneFusion Assay-a rapid, fully automated cartridge-based platform that infers NTRK1/2/3 fusions through 3'-5' expression imbalance-across a retrospective, fusion-enriched cohort of 193 tissue and cytology specimens from MD Anderson Cancer Center and Mayo Clinic, all of which had prior RNA-based next-generation sequencing profiling. Of 108 NTRK gene fusions detected by next-generation sequencing profiling, 67 (62.0%) were reported as "Detected" by the Idylla GeneFusion Assay. When analysis was restricted to definitive "Detected" and "Not Detected" results (n=147), the assay demonstrated high concordance with next-generation sequencing, with positive percent agreement and negative percent agreement of 95.7% and 100%, respectively, with the strongest performance for NTRK3. Including "Equivocal" results as positive increased sensitivity (positive percent agreement 96.3%) with a modest reduction in specificity (negative percent agreement 93.9%, n=190). Most "Invalid" results were attributable to RNA degradation and resolved with freshly cut sections. These findings support the Idylla GeneFusion Assay as a rapid and practical frontline tool for NTRK fusion detection, particularly in settings with limited tissue or need for expedited decision-making, with reflex next-generation sequencing recommended for "Equivocal" cases or when fusion partner identification is required.